Last reviewed · How we verify

Nicotine Lozenges

GlaxoSmithKline · Phase 3 active Small molecule

Nicotine lozenges work by releasing nicotine into the bloodstream to help manage withdrawal symptoms and cravings associated with smoking cessation.

Nicotine lozenges work by releasing nicotine into the bloodstream to help manage withdrawal symptoms and cravings associated with smoking cessation. Used for Smoking cessation.

At a glance

Generic nameNicotine Lozenges
Also known asCommit nicotine lozenge, NRT
SponsorGlaxoSmithKline
Drug classNicotine replacement therapy
ModalitySmall molecule
Therapeutic areaAddiction
PhasePhase 3

Mechanism of action

Nicotine lozenges are designed to provide a controlled release of nicotine, which helps to alleviate withdrawal symptoms and cravings. This can make it easier for individuals to quit smoking by reducing the discomfort associated with nicotine withdrawal.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results